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Abstract: Serine protease inhibitors (serpins) regulate coagulation and inflammation. Heparin, a glycosaminoglycan, is an 
important cofactor for modulation of the inhibitory function of mammalian serpins. The secreted myxoma viral serpin, 
Serp-1 exerts profound anti-inflammatory activity in a wide range of animal models. Serp-1 anti-inflammatory and anti-
atherogenic activity is dependent upon inhibition of the uPA / uPA receptor thrombolytic complex. We demonstrate here 
that heparin binds to Serp-1 and enhances Serp-1 inhibition of thrombin, a human pro-thrombotic serine protease, in vitro, 
altering inhibitory activity to a more predominant anti-thrombotic activity. Heparin also facilitates the simultaneous 
thrombin-mediated cleavage of Serp-1 and prevents formation of a serpin-typical SDS-resistant complex, implying mutual 
neutralization of Serp-1 and thrombin. In a cell-based assay, heparin facilitates Serp-1 reversal of cellular activation by 
stabilizing cellular membrane fluidity in thrombin-activated monocytes. In conclusion, heparin and other GAGs serve as 
cofactors enhancing Serp-1 regulation of local thrombotic and inflammatory pathways. 
Keywords: Serpin, heparin, myxoma virus, thrombosis, GAGs, thrombin. 
INTRODUCTION 
  Serp-1 is a secreted protein encoded by myxoma virus, a 
rabbit leporipoxvirus. This viral protein belongs to the serine 
protease inhibitor (serpin) superfamily (McFadden J Leuko 
Biol 1995) [1]. Previous investigations using a Serp-1 
‘knock-out’ virus have demonstrated that Serp-1 mediates 
blockade of host inflammatory responses to myxoma viral 
infections in European rabbits (Upton Virology 1990) [2] 
(Macen Virology 1993) [3]. Infusion of purified Serp-1 pro-
tein also significantly reduces host inflammatory responses 
in a wide range of animal models, including angioplasty in-
jury, transplant rejection and arthritis (Lucas J Immuno 
2004) [4]. This viral protein is currently under investigation 
in clinical trials as a new class of biopharmaceutical to treat 
human inflammation-based disorders such as acute coronary 
syndromes.  
  The underlying mechanism of Serp-1 anti-inflammatory 
activity is believed to impact multiple inflammation path-
ways, including the inhibition of several mammalian host 
serine proteases, specifically tissue- and urokinase-type 
plasminogen activators (tPA and uPA), and plasmin. Serp-1 
also binds and inhibits factor Xa and is itself cleaved and 
inhibited by thrombin in vitro under simulated physiological 
conditions and concentrations (Viswanathan Thromb Hae-
most 2006) [5] (Lomas J Biol Chem 1993) [6] (Nash J Biol  
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Chem 1998) [7]. Site-directed mutagenesis within the Serp-1 
reactive center loop (RCL) has demonstrated that the P1-P1’ 
amino acid residues (Arg-Asn) as well as the P2-P7 amino 
acid residues are critical for Serp-1’s anti-inflammatory 
functions (Dai J Biol Chem 2006) [8]. In addition, expres-
sion of the uPA-receptor (uPAR) at local injury sites is a 
prerequisite for Serp-1 induced attenuation of vascular in-
flammatory responses and subsequent atheromatous plaque 
development (Dai J Biol Chem 2003) [9]. These data suggest 
that a pathway mediated by the uPA / uPAR system can be 
blocked by the viral serpin in host inflammation responses. 
While the inhibition of the uPA / uPAR complex is noted to 
be important to Serp-1 anti-inflammatory activity, the role of 
Serp-1 interactions with factor Xa and thrombin in this same 
anti-inflammatory activity is not defined.  
  Thrombin is a pluripotent enzyme that activates many 
cells and modulates the coagulation process involved in the 
inflammatory response system (Viles-Gonzalex Am Heart J 
2005) [10]. Several endogenous serpins are known to inhibit 
thrombin activity and regulate thrombosis. Among them, 
anti-thrombin-III (AT-III) is the best-known serpin anti-
coagulant factor that inhibits thrombin activity and prevents 
blood clotting (Dementiev Nat Struc Mol Biol 2004) [11] (Li 
Nat Struct Mol Biol 2004) [12]. In the presence of cofactor 
heparin, AT-III can inhibit thrombin activity with greater 
association rates.  
  Heparin is a member of a family of sulfated polysaccha-
rides known as glycosaminoglycans (GAGs). This group of 
molecules includes heparan sulfate, heparin, chondroitin 
sulfate, and dermatan sulfate (Taylor FASEB J 2006) [15]. 
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interact with proteins ranging from proteases (such as those 
involved in blood coagulation) and extracellular signaling 
molecules (such as chemokines and growth factors), to lipid- 
and membrane-binding proteins. GAGs participate in host 
coagulant and inflammatory responses by interacting with 
the above mentioned proteins that regulate blood clotting, 
cell adhesion, localization, chemotaxis and migration (Han-
del Annu Rev Biochem 2005) [16].  
  The mechanism of AT-III inhibition of thrombin is medi-
ated predominantly through binding to heparin (GAG) mole-
cules in order to target thrombin more easily (Gettins Chem 
Rev 2002) [13]. This heparin / AT-III interaction is the basis 
for the use of heparin infusion as anti-coagulant treatments 
in patients with unstable coronary disease and myocardial 
infarctions, cerebrovascular and peripheral arterial thrombo-
embolization and during vascular surgery. A heparin-binding 
domain has been identified in the AT-III amino acid se-
quence. This domain is conserved in other human serpins, 
such as heparin cofactor II, protease nexin 1 and plasmino-
gen activator inhibitor type-1 (PAI-1) (Ehrlich Biochem 
1991) [14]. The serpins with this conserved domain have the 
ability to bind to heparin. In turn, heparin acts as a cofactor 
to facilitate the serpin interaction with thrombin and to regu-
late thrombotic and inflammatory processes.  
  Interactions between GAGs and the viral serpin (Serp-1) 
and the effects of heparin on Serp-1 inhibition of serine pro-
teinases in the thrombotic and thrombolytic cascades have 
not been investigated. In this study, we examine the ability 
of Serp-1 to bind heparin and evaluate heparin-meditated 
effects on Serp-1/protease interactions. This study provides 
new insights into the role and effect of heparin cofactors on 
the viral serpin-mediated inhibitory activity and is important 
for further elucidation of the mechanism of action and de-
velopment of this new class of anti-inflammatory reagents. 
MATERIALS AND METHODS 
Proteins and Reagents 
  Recombinant Serp-1 protein was expressed in the trans-
formed-CHO cell line and purified with the traditional chro-
matograph method as described (Nash J Biol Chem 1998) 
[7]. In brief, medium containing secreted viral proteins is 
purified by sequential column chromatographic separations 
as follows: 1) Hi-trap Q (Pharmacia) washed with 20mM 
Tris, pH8.0 and eluted with 75mM NaH2PO4, pH7.0; 2) 
Copper co-operated chelating column, washed with 0.1M 
NH4Cl and eluted with 1M NH4Cl; 3) Superdex 75 gel 
filtration column, buffer exchanged to 150mM NaCl, 25mM 
Tris, pH8.0. Eluates are analyzed by Western blot. Serpin 
concentration is measured by ELISA (Lau J boil Chem 
2004) [24] (Rezaie Protein Sci 1998) [25] (Schechter Meth-
ods 2004) [26] (Silverman Methods 2004) [27] (Esmon Br J 
Haematol 2005) [28] and single band purity was > 90% by 
Coomassie blue staining in SDS-PAGE (sodium dodecyl 
sulfate polyacrylamide gel electrophoresis) (Nash J Biol 
Chem 1998) [7] (Dai J Biol Chem 2006) [8] (Dai J Biol 
Chem 2003) [9]. The concentration of purified Serp-1 was 
determined by absorbance at 280 nm using a molar extinc-
tion coefficient of 32,700 M
-1 cm
-1 (Nash J Biol Chem 1998) 
[7]. Five serine proteases, human tissue-type plasminogen 
activator (tPA) (BD Biosciences), human urokinase-type 
(uPA) (Sigma), plasmin (Sigma), thrombin (Sigma), and 
factor Xa (Chromogenix), were used in this study. Five 
chromogenic substrates were used in this study. They were: 
(1) Pefachrom-uPA for uPA; (2) Pefachrom-tPA for tPA; (3) 
S-2251 for plasmin; (4) S-2222 for factor Xa, and (5) S-2238 
for thrombin. The first two were purchased from Pentapharm 
and 3, 4, and 5 were obtained from Chromogenix. Unfrac-
tionated heparin (average 25 polysaccharide units) was pur-
chased from Leo Pharmaceuticals. Polybrene was purchased 
from Sigma. 
Heparin/Sepharose Bead-Binding and Electrophorseis 
  Heparin/Sepharose beads were prepared from the HiTrap 
Heparin column (Amersham). The heparin bead resin was 
washed three times with 1 x PBS before the pull-down ex-
periment. Serp-1 (50 ng) in PBS buffer (pH 7.4) was added 
to 15 l of the bead resin and incubated at 37°C for one 
hour. After incubation, 400 l of PBS was added to wash the 
heparin beads. The beads were spun down at 13,000 rpm for 
1 minute. The wash step was repeated three times to remove 
unbound Serp-1 from the resin. If an elution step was re-
quired, the Serp-1 bound beads were incubated with 100 l 
of NaCl solution at different concentrations (0 M, 1 M, or 2 
M). After a 10 minute incubation at room temperature, the 
beads were washed three times as described above. The 
treated heparin beads were dissolved in the SDS-PAGE load-
ing buffer, heated at 95 °C for 3 minutes, and analyzed in 
12% gels. After electrophoresis, the separated proteins on 
gels were transferred to nitrocellulose membrane for im-
munoblot analysis. The membranes were blocked with 5% 
skim milk in PBS buffer overnight at 4°C. A mouse anti-
Serp-1 monoclonal antibody (mAb) was incubated with the 
membrane for Serp-1 protein detection. Goat anti-mouse IgG 
antibody, labeled with horseradish peroxidase, was used for 
detection of the mouse mAb and signal was detected on Ko-
dak X-ray film by using the ECL Western blotting detection 
kit (GE Health Care Inc.).  
  In order to examine the formation of a Serp-1/thrombin 
complex band and degradation of Serp-1 bands in the pres-
ence of heparin, Serp-1 was pre-incubated with heparin be-
fore adding this mixture into the thrombin reaction. Samples 
were analyzed using 12% gels and stained with a Gelcode 
staining kit (Pierce). Gel images were recorded by the Gel-
Doc system (Bio-Rad). 
Heparin / Sepharose Column Chromatography 
  Heparin binding affinity analysis was performed using a 
fast protein liquid chromatography (FPLC) system (Pharma-
cia LKB Biotechnology Inc.) and a 1-ml column of pre-
packed Heparin/Sepharose resin (HiTrap, Amersham). 2 ml 
of Serp-1 solution (1 mg/ml) was loaded on the column. Af-
ter washing with two column volumes of PBS, the Serp-1 
protein was eluted by NaCl solution with a linear increase of 
concentrations from 0 M to 1 M. The elution buffer flow rate 
was 1 ml/min. Protein elution was monitored by detecting 
absorbance at 280 nm. The binding affinity was expressed as 
the salt elution concentration, at which the absorbance of 280 
nm reached the maximum peak. The estimated salt elution 
concentration value was taken as the mean of three repeated 
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Chromogenic Assays 
  Serp-1 inhibitory activity was evaluated with five prote-
ases (tPA, uPA, plasmin, factor Xa, and thrombin) in the 
presence and absence of heparin. These assays were per-
formed in microtitre plates (Nunc). Serp-1 (25 l) was incu-
bated with 25 l of enzyme solution at room temperature for 
at least one hour to allow Serp-1 binding and inhibition of 
protease activity. After the incubation, 10 μl of chromogenic 
substrate was added into the reaction. The 96-well plate was 
covered and placed in a wet box (preventing evaporation) for 
overnight incubation at 37 °C. After a 17-hour incubation, 
the plate was read at 405nm by a microplate reader (Bio-Tek 
Instrument). The reaction buffer (100 mM NaCl, 2 mM 
CaCl2, 100 mM Tris-HCl, pH 7.5, Triton X-100, 0.005%) 
was used for dilutions of proteases, Serp-1, and chromogenic 
substrate. The residual protease activity was calculated by 
comparing to the control sample, which contained no Serp-1. 
In those reactions containing heparin, Serp-1 was pre-
incubated with heparin solution at indicated units before the 
addition of protease. The enhancing effects of heparin were 
elucidated by comparing heparin-containing and heparin-free 
groups in the reactions.  
  To measure inhibition rates for thrombin, Serp-1 (5 l) 
was added into 30 l of the reaction buffer containing 1 
mg/ml BSA. 5 l of thrombin was added into the reaction to 
interact with Serp-1 for different time durations (1 minute to 
20 minutes) followed by dilution (7.5 fold) with the reaction 
buffer containing 4 mg/ml Polybrene. Chromogenic sub-
strate (S-2238) was added into the reaction (final concentra-
tion: 1 mM) and the absorbance at 405 nm was measured 
kinetically for 30 minutes with 1 minute/interval at room 
temperature. The remaining activity of uninhibited thrombin 
was calculated from the rate of chromogenic substrate hy-
drolysis. The second order association rate constant (Ka) of 
thrombin inactivation by serpins was calculated by fitting the 
time dependent change of thrombin activity to the following 
equation, 
Ka=  (-ln  a)  /t[I]        (Eq.  1) 
where ‘a’ is residual protease activity, ‘t’ is time, and ‘[I]’ is 
the serpin concentration (Rezaie J Biol Chem 1995) [17]. In 
all experiments, it was ensured that less than 10% of the 
chromogenic substrate was utilized and all inhibition assays 
were performed by a time course that obtained at least 50% 
enzyme inhibition for calculation of inhibition rates. All as-
says were performed in triplicate.  
Cellular Membrane Fluidity Assay 
  Cellular membrane fluidity provides a measure of cellu-
lar activation responses. Experiments analyzing membrane 
fluidity were performed according to previously described 
methods (Viswanathan Thromb Haemost 2006) [5]. Briefly, 
the human monocytic cell line (THP-1) was cultured in 
RPMI medium supplemented with 10% Fetal Bovine Serum 
(Invitrogen Canada, Burlington, Canada), Penicillin (1 U/ml) 
and Streptomycin (1 mg/ml). Cells at 1 x 10^6 cell/ml were 
labeled with 0.8 M of BPP (1,3-Bis (1-pyrenyl) propane) 
(Molecular Probes Inc., Eugene, USA) three hours prior to 
cell activation. Cells were activated by thrombin (1 U/ml) for 
one hour, washed, resuspended in growth medium and 
treated with Serp-1 (500 ng/ml) for one hour at 37°C In the 
heparin-treated group, Serp-1 was mixed with 0.1 U/ml 
heparin prior to being adding to cells. After the end of one 
hour, cells were washed to remove excess fluorescent probe 
and monomer, and excimer fluorescence emission intensities 
were measured at 390nm and 485nm respectively during 
excitation at 320nm using a fluorescent dual wavelength 
reader (Fluoroskan, Thermolab system, USA). The ratio of 
excimer fluorescence to monomer fluorescence (Iex/Imon) is 
used as a measure of membrane fluidity (Viswanathan 
Thromb Haemost 2006) [5]. Changes in membrane fluidity 
among different cell treatment groups were assessed by 
analysis of variance (ANOVA). P-values less than or equal 
to 0.05 (p < 0.05) were considered significant.  
RESULTS 
Serp-1 Binds Heparin 
  Heparin-coated sepharose beads were used to examine 
the capacity of Serp-1 to bind individual serine proteases. 
Serp-1 protein binds to heparin-coated beads and is co-
precipitated with beads after centrifugation (Fig. 1A, lane 2). 
Furthermore, Serp-1 bound to heparin coated beads was 
eluted by using different concentrations of salt solution 
(NaCl) (Fig. 1A, lane 3 and 4).  
  The affinity of Serp-1 for binding heparin was measured 
by using heparin-sepharose columns. Serp-1 bound to the 
Table 1.  Heparin affinity and uPA inhibition of native and heated Serp-1 Proteins 
Samples  Proportion* (%)  Heparin Affinity** (mM NaCl)  uPA Inhibition 
Native Serp-1       
Unbound 5  0  No 
Peak 1  95  555  Yes 
Heated Serp-1       
Unbound 6  0  No 
Peak 1  86  400  No 
Peak 2  8  680  Yes 
*Protein concentration was measured using the Bio-Rad Protein Assay Kit. 
**Heparin affinity is given as the salt concentration required for elution. 
***Measured in uPA activity assay. Heparin Binding Alters Viral Serpin Activity  The Open Biochemistry Journal, 2008, Volume 2    9 
heparin column in a neutral pH environment (pH 7.4) and 
was eluted as a single peak with maximum OD280 absorb-
ency at an equivalent salt concentration of 555 mM (Fig. 
1B). In addition, the capacity of heat-inactivated Serp-1 to 
bind to heparin columns was assessed. To denature Serp-1 
by heating, active Serp-1 solution was incubated at 75°C for 
30 minutes. This denatured Serp-1 was analyzed by FPLC. 
The heat-treated Serp-1 was still able to bind to the heparin 
column, but the binding affinity was reduced from 555 mM 
(active Serp-1) to 400 mM NaCl (Fig. 1C). The main peak of 
heat inactivated Serp-1 completely lost inhibitory activity in 
the uPA activity assay (Table 1). This study indicates that 
the heparin binding ability of Serp-1 is independent of its 
inhibitory activity for uPA.  
  A small portion (8%) of the heat-denatured Serp-1 was 
also observed to be eluted at 680 mM NaCl solution (Peak 2 
in Fig. 1C). This fraction is speculated to represent polymers 
of Serp-1 and retained weaker inhibitory activity for uPA; 
40-fold less than unheated Serp-1 (data not shown). We 
aligned the Serp-1 amino acid sequence with that of human 
PAI-1, which has a conserved heparin binding domain lo-
cated in the helix D domain (Berkenpas Embo J 1995) [18]. 
Of thirteen amino acids, four amino acids in Serp-1 are iden-
tical to PAI-1 (31% homology) in this area (Fig. 1D). There 
are three basic amino acid residues (Arg6, His7, Lys10) in 
the PAI-1 domain, while there is only one basic amino acid 
(Arg6) in the Serp-1 domain. The arginine residue is a strong 
basic amino acid residue and has been proved critical for 
heparin binding ability in both human and murine PAI-1 
(Ehrlich J Biol Chem 1992) [19] (Xu J Biol Chem 2004) 
[20]. We performed site-directed mutagenesis at position 6 
to replace this arginine with alanine. The mutated Serp-1 was 
still capable of binding to heparin (data not shown). These 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Serp-1 binds to heparin in vitro. In a pull-down experiment with heparin/sepharose beads (A), Serp-1 (100 ng) was incubated with 
15 l of heparin/sepharose beads (Amersham) for one hour at 37 °C. After Serp-1 bound to heparin beads, 100 l of NaCl solution at differ-
ent concentrations (0 M, 1 M, and 2 M) was added to elute Serp-1 from the heparin beads. The elution was performed at room temperature 
for 10 minutes. After elution, the Serp-1 heparin beads were loaded on SDS-PAGE gel for electrophoresis and followed by the immunoblot 
detection with the anti-Serp-1 monoclonal antibody. 100 ng Serp-1 positive control shown in lane 1. FPLC chromatograph analysis: native 
(B) and heat-inactivated (C) Serp-1 were loaded onto the heparin columns and eluted with a NaCl gradient. The absorbance at 280 nm was 
monitored. A representative elution curve is presented from three repeat experiments. X axis at bottom indicates running time of the column 
analysis. X axis at top indicates collecting fractions (1 ml/fraction). Y axis indicates absorbance at 280 nm. Amino acid sequence alignment 
(D). Human PAI-1 helix D heparin-binding domain (13 amino acid residues) aligns with the Serp-1 sequence by MacVector (version 3). The 
residue (Arg6) in Serp-1 has been mutated (boxed) to examine its significance of the heparin binding ability (see text). The identical amino 
acids in both sequences are dotted and the similar amino acids are starred underneath. 3-D serpin structure showing the relative positions 
between helix D (hD) and the reactive center loop (RCL) is adapted from Gettins (Chem Rev 2002). 
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Fig. (2). Heparin enhancing effect in the inhibition of thrombin by Serp-1. Thrombin at a fixed amount (0.002 NIH units) was incubated with 
Serp-1 at various amounts (A-H) in the presence or absence of heparin at 37 °C for one hour. The chromogenic substrate (S-2238) was added 
into the reaction and color development was monitored every hour for first 6 hours and at 12 and 24 hours thereafter (X axis). The residual 
thrombin activity (Y axis) was expressed as percentage of the control sample, which contained no Serp-1. 
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findings suggest that the viral serpin, Serp-1, may have a 
different structural binding domain than PAI-1 that contrib-
utes to GAG/polyanion binding ability.  
Heparin Facilitates Interaction Between Serp-1 and 
Thrombin 
  We evaluated heparin-mediated effects on Serp-1 inhibi-
tion of the activity of five target proteases (tPA, uPA, plas-
min, factor Xa, and thrombin) by using cognate chromogenic 
substrate assays. No heparin enhancing effect was observed 
for Serp-1 inhibition of tPA, uPA, plasmin, nor factor Xa in 
these assays (data not shown). However, Serp-1 mediated 
inhibition of thrombin was enhanced by adding heparin to 
the Serp-1/thrombin reaction (Fig. 2). In the absence of 
heparin, Serp-1 at 1250 ng, 600 ng, and 300 ng inhibited 
75%, 65%, and 25% of thrombin activity, respectively (Fig. 
2. A, B, C, square points). Serp-1 did not inhibit thrombin 
activity at or below 150 ng concentrations in the reaction 
(Fig. 2D to H, square points). With the addition of heparin, 
Serp-1 at low amounts could resume its inhibition of throm-
bin. For example, 19 ng of Serp-1 (Fig. 2F) did not show any 
inhibitory activity for thrombin in the absence of heparin 
(square points), but was able to inhibit 75% of thrombin in 
the presence of heparin (0.2 IU) (triangle points), which cor-
responds to the ability of Serp-1 to inhibit thrombin at a con-
centration of 1250 ng without heparin (Compare Fig 2A and 
2F). Thus, addition of heparin enhanced Serp-1 inhibition of 
thrombin approximately 66 fold in the thrombin inhibition 
reaction.  
  It is noteworthy that there was a U-shaped inhibitory 
curve observed in the lowest Serp-1 inhibitions (Fig. 2G and 
2H). This indicates that the active form of thrombin is re-
leased from the Serp-1/thrombin complex after the initial 
inhibition. Thus, heparin may facilitate the interaction be-
tween Serp-1 and thrombin; however, heparin is unable to 
prevent the subsequent release of active thrombin from the 
Serp-1/thrombin complex.  
  Heparin also dramatically enhanced the rate of Serp-1 
mediated inhibition of thrombin. For example, Serp-1 at 500 
ng inhibited 86% of thrombin over a 20 minute-period (Fig. 
3A). With the addition of heparin at 0.0035 IU, the inhibition 
rate was greatly accelerated and the inhibition process was 
accomplished within one minute (Fig. 3B). In the absence of 
heparin, the second order association rate constant (Ka) 
value was measured at 9.5 ± 4.5 x 103 by the discontinuous 
assay. With addition of heparin, the inhibition reaction pro-
ceeded so rapidly (< 60 seconds) that no progressive inhibi-
tion curves could be obtained for the calculation of the Ka by 
the current assay.  
Heparin Enhancing Effect Through a Bridging Mecha-
nism  
  To examine whether the ability of heparin to enhance 
Serp-1 mediated inhibition of thrombin was dependent on 
heparin’s presence in the reaction, the effects of five differ-
ent concentrations of heparin were assessed in three non-
inhibitory (38ng, 75ng, and 150ng) Serp-1 reactions (Fig. 4) 
and the residual thrombin activity was plotted as a function 
of heparin units.  
 
 
 
 
 
 
 
 
Fig. (4). Heparin-dependent inhibition of thrombin by Serp-1. 
Thrombin at a fixed amount (0.002 NIH units) was incubated with 
Serp-1 at three non-inhibiting amounts (38, 75, and 150 ng) with 
increasing units of heparin (X axis). The experiment conditions 
were similar to those in Fig. 2 except color generation was moni-
tored at 17 hour after the substrate was added into the reactions. 
The residual thrombin activity (Y axis) was expressed as percentage 
of the control sample, which contained no Serp-1. 
  An inverted bell-shaped curve was observed in these 
analyses. Increasing heparin from 0.02 to 0.2 IU in the reac-
tions produced the maximal enhancement of the Serp-
1/thrombin inhibition reaction. Beyond that point, heparin 
did not further enhance Serp-1’s inhibitory activity. Instead, 
excess heparin (e.g. 10 IU) abolished Serp-1 mediated inhi-
bition. These results strongly suggest that heparin provides a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). A discontinuous assay to measure thrombin inhibition rate 
in the absence (A) and presence (B) of heparin. A fixed amount of 
thrombin (0.125 NIH units) was incubated with Serp-1 (500 ng) at 
room temperature. At indicated time points (1, 3, 5, 10, 15, and 20 
minutes), the chromogenic substrate (S-2238) containing 4 mg/ml 
Polybrene was added to a final concentration of 0.2 mM. Absor-
bance at 405 nm (Y axis) was monitored by kinetic measurement 
every 1 minute for 1800 seconds (X axis) at room temperature. 
Slopes represent the initial reaction velocity from residual throm-
bin and are used to calculate Ka value using the equation described 
in “Materials and Methods”.  
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template or bridge that brings the thrombin protease and ser-
pin into close proximity, thereby facilitating the inhibitory 
process. However, excess heparin is postulated to segregate 
thrombin and Serp-1 onto separate templates, resulting in a 
reduction in the capacity of Serp-1 to inhibit thrombin. This 
observation is consistent with a template/bridge hypothesis 
(Gettins Chem Rev 2002) [13].  
  The enhancing effect of heparin in the Serp-1/thrombin 
interaction was also analyzed by SDS-PAGE (Fig. 5). Native 
Serp-1 migrated as two bands at 96 and 47 kDa (Fig. 5 lane 
8). The high molecular weight band of Serp-1 is thought to 
represent a dimer of the lower band. Human thrombin mi-
grated as doublet bands at 35 kDa (Fig. 5 lane 9). When 
mixed for 20 minutes at room temperature, Serp-1 and 
thrombin formed a serpin-typical complex band at 82 kDa 
(arrow at left, top, Fig. 5A). In the Serp-1/thrombin reaction, 
Serp-1 was also cleaved by thrombin and formed a cleaved 
band migrating at 37 kDa (arrow at left, bottom, Fig. 5A). In 
the absence of heparin (Fig. 5A), both the Serp-1/thrombin 
complex and cleaved Serp-1 bands increased along with the 
initial increase in thrombin in the reaction (Fig. 5A lane 5-7). 
Once native Serp-1 was no longer present, there was no fur-
ther increase in the levels of both cleaved Serp-1 and throm-
bin/Serp-1 complex (Fig. 5A lanes 1-4). In the presence of 
heparin, the cleaved Serp-1 band became predominant and 
the complex band became invisible as heparin in the reac-
tions increased from 0.001 IU (Fig. 5B) to 0.01 IU (Fig. 5C). 
It indicated that heparin facilitated thrombin cleavage of 
Serp-1 in the reaction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Effect of reactant concentrations of thrombin and heparin 
in the reaction of Serp-1 and thrombin. 10 L samples were incu-
bated at room temperature for 20 minutes, followed by adding the 
SDS-PAGE loading buffer, electrophoresis on a 12% gel, and stain-
ing with Coomassie blue kit (Gel-Code Blue, Pierce). Lanes 1 to 8 
contained 1 μg Serp-1. Lanes 1 and 9 contained 2 NIH units throm-
bin; lane 2, 1 NIH unit thrombin; lane 3, 0.5 NIH units thrombin; 
lane 4, 0.25 NIH units thrombin; lane 5, 0.12 NIH units thrombin; 
lane 6, 0.06 NIH units thrombin; lane 7, 0.03 NIH units thrombin. 
(A) There was no heparin added into the reaction. Heparin at 0.001 
IU (B) and 0.01 IU (C) was added prior to the thrombin reaction. S 
lane contained molecular markers (kDa). Arrows at left indicate the 
complex band (top) and cleaved Serp-1 band (bottom). Arrowheads 
at right indicate the native Serp-1 and thrombin bands, respectively. 
  To further investigate the cleavage process of Serp-1 by 
thrombin in the presence of heparin, we increased the 
amounts of heparin in the thrombin/Serp-1 reactions and 
monitored the cleaved Serp-1 band by SDS-PAGE. It be-
came obvious that formation of the cleavage band of Serp-1 
was dependent on the amount of heparin units added. In this 
experiment, each sample contained the same amount of Serp-
1 (1 g) and thrombin (0.03 units), but different units of 
heparin varied from 0.0001 units (lane 2) to 0.1 units (lane 
7). After incubation at room temperature for 30 minutes, the 
reaction was stopped and the samples were analyzed by 
SDS-PAGE (Fig. 6A). The top band represents the un-
cleaved, native Serp-1 monomer (47 kDa) and bottom band 
represents the thrombin-cleaved Serp-1 (37 kDa). The opti-
cal density of the cleaved band was measured and plotted 
against the heparin units presented in the reaction (Fig. 6B). 
In the absence of heparin, there was only 20% of Serp-1 
cleaved by thrombin in the reaction (lane 1). Increase of 
heparin unit from 0.0001 to 0.001 facilitated the cleavage of 
Serp-1 band by thrombin (lane 2 and 3). When heparin units 
reached at 0.005, 100% of native Serp-1 was cleaved by 
thrombin (lane 4). Further increase of heparin to 0.1 units did 
not increase the cleaved Serp-1 band. In opposite, excessive 
heparin prevented thrombin to cleave Serp-1 and the propor-
tion of cleaved Serp-1 in the reaction was falling back to 
20% (lane 7). Thus, the cleavage of Serp-1 by thrombin had 
a typical bell-shaped curve dependent on the amount of 
heparin presented in the reaction (Fig. 6B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Cleavage of Serp-1 by thrombin in the presence of heparin. 
(A) The experimental conditions were identical to those in Fig. 5. 
Lanes 1 to 7 contained 1 g Serp-1 and 0.03 NIH units thrombin. 
Lane 8 contained 1 g Serp-1. Prior to adding thrombin into the 
reaction, heparin was incubated with Serp-1 at room temperature 
for 30 minutes. Lane 1, 0 IU heparin; lane 2, 0.0001 IU heparin; 
lane 3, 0.001 IU heparin; lane 4, 0.005 IU heparin; lane 5, 0.01 IU 
heparin; lane 6, 0.05 IU heparin; lane 7, 0.1 IU heparin. (B). Protein 
band density was scanned by the Gel-doc system (Bio-Rad) and 
plotted as a function of heparin units. 
Cellular Membrane Fluidity Assay 
  Changes in plasma membrane fluidity on activated cells 
reflect the cellular activation state (Hollan Haematologia 
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1996) [21]. Heparin can facilitate various circulating activa-
tors to activate immune cells. To assess the potential role of 
this heparin-dependent inhibition of thrombin on Serp-1 me-
diated anti-inflammatory activities, we measured changes in 
cellular core membrane fluidity after stimulation by throm-
bin and after treatment with Serp-1 in the absence and pres-
ence of heparin (Fig. 7). In the THP-1 human monocyte cell 
line, neither thrombin (p=0.113) nor Serp-1 (p=0.553) nor 
heparin (p=0.158) when given alone caused significant 
changes in the core membrane fluidity (Fig. 7). However, in 
the presence of heparin, thrombin significant increased 
(p<0.001) the measured membrane fluidity when compared 
to saline control. Serp-1, when added to thrombin treated 
cells, was capable of reversing thrombin mediated changes 
in membrane fluidity, returning the Iex/Imon level to normal 
(p=0.793) (Fig. 7). In the absence of heparin, Serp-1 was 
also capable of reducing the increase in membrane fluidity 
(Iex/Imon), but this reduction did not reach a significant level 
(p=0.298) in this study.  
 
 
 
 
 
 
 
 
 
 
Fig. (7). Core membrane fluidity measured using 1,3-Bis-
pyrenylpropane (BPP) fluorescent probe. Membrane fluidity in the 
human monocytic cells (THP-1) was measured after incubation 
with different activators and inhibitors. Serp-1 (p=0.553), thrombin 
(p=0.113), or heparin (p=0.158) alone did not cause membrane 
fluidity changes when compared to control (saline). In the presence 
of heparin (0.1 U/ml), thrombin increased membrane fluidity sig-
nificantly (p<0.001). Serp-1 reversed the heparin-mediated activa-
tion, bringing the fluidity level back to a normal level (p < 0.001 
compared to heparin activation; p=0.793 on comparison to saline, 
heparin or thrombin alone without Serp-1). *Significantly different 
(p<0.001) compared to control saline. 
  These findings indicate that Serp-1 is capable of revers- 
ing thrombin induced physiological changes in cellular acti- 
vation when given in the presence of concomitant heparin  
treatment, as measured by altered membrane fluidity. Serp-1  
thus blocked thrombin induced changes in human monocyte  
in vitro activation through a heparin dependent interaction  
suggesting that Serp-1 mediated anti-inflammatory activities  
may also depend in part on inhibition of thrombin, a pro- 
thrombotic serine protease in addition to inhibition of factor  
Xa and the thrombolytic proteases uPA, tPA and plasmin.  
DISCUSSION 
  We demonstrate here that Serp-1 binds to heparin and 
that the heparin-binding event facilitates the interaction be-
tween Serp-1 and a human serine protease, thrombin in the 
pro-thrombotic (clot forming) pathway. Thrombin is a piv-
otal protease that plays a central role in initiating the throm-
botic process by activating various host cells and regulating 
coagulation, as well as inflammation. Inhibition of thrombin 
activity can significantly reduce thrombosis and alleviate 
local inflammation. This study shows that the viral serpin 
Serp-1, which demonstrates in vitro anti-thrombolysis activ-
ity, can efficiently inhibit thrombin activity in the presence 
of heparin. In addition, Serp-1 can also reverse monocyte 
activation by stabilizing cellular membrane fluidity in the 
presence of heparin. Thus, heparin as a cofactor can facilitate 
the capacity of this viral serpin to exert its potent anti-
inflammatory functions through modulation of the anti-
thrombotic pathway.  
  Heparin as a cofactor binds to several human serpins with 
various binding affinities, which is generally expressed as 
the salt concentration required for elution of a given serpin 
from heparin columns. High salt concentration indicates high 
affinity of a serpin binding to heparin. For example, anti-
thrombin-III was eluted at 750 mM; protein C inhibitor at 
350 mM; heparin cofactor at 220 mM (Pratt J Biol Chem 
1992; 267(13): 8795-8801.) [22]; factor Xa at 446 mM (Pratt 
J Biol Chem 1992; 267(13): 8789-8794) [23], and PAI-1 at 
316 mM (Ehrlich Biochem 1991) [14]. Such heparin column 
analysis is also used for characterization of the chemokine-
GAG binding affinities (Handel Annu Rev Biochem 2005) 
[16]. For example, the wild type CC chemokine, MCP-1, has 
a heparin binding affinity measured at 486 mM (Lau J boil 
Chem 2004) [24]. We used heparin columns to measure 
Serp-1’s heparin-binding affinity. The results show that ac-
tive Serp-1 has a binding affinity at 555 mM. It is not sur-
prising that AT-III has the highest binding affinity among 
these serpins (750 mM). Heparin’s most prominent target is 
thrombin which binds glycosaminoglycan (GAG) in order to 
trigger its anticoagulant function in the clotting cascade. In 
contrast, Serp-1 has a moderate binding affinity in compari-
son with other human heparin-dependent serpins and GAG-
binding chemokines. It is possible for Serp-1 to compete 
with endogenous proteins, such as clotting factors and/or 
chemokines, to bind to heparin and heparin-like GAG mole-
cules  in vivo and apply its anti-inflammatory functions 
through the anticoagulant pathway and GAG-mediated che-
motaxis pathway.  
  In the anticoagulant pathway, heparin enhances the in-
hibitory abilities of serpins involved in the clot cascade 
through two mechanisms: (i) a bridging mechanism and (ii) a 
conformational-based mechanism (Gettins Chem Rev 2002) 
[13]. In the bridging mechanism, both serpin and protease 
simultaneously bind to a heparin molecule, allowing heparin 
to serve as a template to bring the two reactants together and 
facilitate subsequent interactions. This mechanism is charac-
terized by a bell-shaped inhibitory curve depending on hepa-
rin concentration. We observed the typical bell-shaped curve 
in the heparin-assisted inhibition of thrombin by Serp-1 (Fig. 
4). Furthermore, for the first time we observed the bell-
shaped curve effect in the Serp-1 cleavage process caused by 
thrombin in the reaction. This observation confirms the mu-
tual neutralization of Serp-1 and thrombin in the reaction. 
Heparin can serve as a template to facilitate both processes. 
  It is unknown yet whether the heparin-binding event also 
causes Serp-1’s conformational changes. We observed that a 
low molecular weight heparin, with an average length of 15 
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monosaccharide units, could still enhance Serp-1 inhibition 
of thrombin (data not shown). The absolute length of heparin 
oligosaccharide units required in the Serp-1/thrombin inhibi-
tion needs to be further determined.  
  Three steps occur consequentially when a serpin interact-
ing with its target protease (Gettins Chem Rev 2002) [13] 
(Schechter Methods 2004) [26]. These steps are (i) covalent 
complex formation, (ii) complex breakdown, and (iii) sub-
strate turnover. Therefore, three parameters are used to de-
fine the effectiveness of serpin inhibition of a given target 
protease: stoichiometry of inhibition (SI), stability of the 
complex (SDS-resistant band), and the second order associa-
tion rate constant (Ka). An inhibitory serpin should have its 
SI near 1:1, form a SDS-stable complex with target protease, 
and have a Ka value at approximately 104 M-1 s-1 to inhibit 
a target protease (Silverman Methods 2004) [27]. According 
to these criteria, Serp-1 was initially not considered to be an 
inhibitor of thrombin, because there was no SDS-stable 
complex band observed. Only the cleaved Serp-1 appeared in 
SDS-PAGE analysis (Lomas J Biol Chem 1993) [6]. It was 
later revealed that the Serp-1 / thrombin complex did exist, 
but with a very short half-life time (less than 60 minutes) 
(Nash J Biol Chem 1998) [7]. Also, there was a high binding 
stoichiometry ratio (13:1) measured in the Serp-1/thrombin 
interaction with a second order association rate constant (Ka) 
toward thrombin measured at 2.6 x 104 M-1 s-1 by the “slow 
binding” assay (Nash J Biol Chem 1998) [7]. It has been 
debated that Serp-1 does not act as an efficient inhibitor for 
human thrombin. Discovery of the heparin-binding ability of 
Serp-1 has altered this argument, because heparin not only 
greatly enhanced Serp-1’s capacity to inhibit thrombin (Fig. 
3), but also accelerated the cleavage of Serp-1 by thrombin 
in the reaction (Fig. 6). The detailed mechanism of the Serp-
1/thrombin interaction, especially in the presence of heparin, 
will require further definition.  
  Inflammation and coagulation processes are linked to 
form an integrated host defense system (Esmon Br J Haema-
tol 2005) [28]. Thrombin is the final protease generated in 
the blood coagulation cascade. It is responsible for cleaving 
fibrinogen to form fibrin. In addition, thrombin also activates 
platelets, monocytes and macrophages to initiate the cellular 
responses in the thrombotic process. Previous studies show 
that Serp-1 can attenuate platelet and monocyte adhesion to 
fibronectin and collagen. The secondary messages of intra-
cellular calcium concentration and membrane fluidity also 
indicate that Serp-1 can reverse the innate cellular activation 
stimulated by several mediators including thrombin (Viswa-
nathan Thromb Haemost 2006) [5]. In this study, we demon-
strate that Serp-1 can reverse the cellular membrane fluidity 
level caused by thrombin stimulation in the presence of 
heparin (Fig. 7). There are two possibilities to explain this 
observation: (i) heparin facilitates Serp-1 to inactivate 
thrombin activity, therefore, thrombin can no longer interact 
with the target cellular receptors; or (ii) heparin binds to 
Serp-1 and there is no excessive free heparin to stimulate 
thrombin activating on cells. More experiments are needed 
to confirm these assumptions.  
  Heparin and heparin-like GAGs can bind to another 
group of inflammation-mediators: chemokines. In the GAG-
mediated chemotaxis pathway, chemokines bind to GAGs to 
form a gradient in order to recruit various immune cells to 
inflammation sites (Handel Annu Rev Biochem 2005) [16]. 
Since Serp-1 has an ability to bind to heparin, it is possible 
that Serp-1 can compete with these molecules binding to 
heparin and disengage the chemokine / GAG interactions, 
thus, reduce cellular inflammation responses through the 
GAG-mediated chemotaxis pathway.  
  In conclusion, this study confirms that viral Serp-1 is 
able to bind to heparin and that heparin acts as a cofactor to 
facilitate the interaction of Serp-1 with one of its target pro-
teases, thrombin. The discovery of Serp-1’s heparin-binding 
ability opens up new lines of investigation to elucidate the 
mechanisms of action whereby Serp-1 mediates a potent 
anti-inflammatory response against the host defense system.  
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